<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103792</url>
  </required_header>
  <id_info>
    <org_study_id>WG-MMF-1</org_study_id>
    <secondary_id>UMCG-ANCA-MMF-1</secondary_id>
    <nct_id>NCT00103792</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)</brief_title>
  <official_title>Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of a new drug,
      mycophenolate mofetil, for the treatment of relapses of ANCA-associated vasculitis (Wegener's
      granulomatosis or microscopic polyangiitis). Therefore, we compare the standard therapy with
      cyclophosphamide to mycophenolate mofetil.

      The investigators expect mycophenolate mofetil to be less toxic and almost equally effective
      as cyclophosphamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of ANCA-associated vasculitis consists of two phases: remission induction with
      highly effective, but also relatively toxic drugs, and, secondly, after remission is
      achieved, maintenance therapy with less toxic drugs. The standard induction therapy of a
      relapse of Wegener's granulomatosis or microscopic polyangiitis consists of the combination
      of cyclophosphamide and prednisolone. Although this induction therapy is very effective, it
      is very toxic as well.

      Searching for an alternative for cyclophosphamide, we will test the efficacy and safety of a
      new combination therapy with mycophenolate mofetil and prednisolone. We will compare the
      effect and safety of the standard induction therapy with the new therapy. When relapses
      occur, patients will be randomized for either the standard therapy with cyclophosphamide or
      for mycophenolate mofetil.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>remission induction rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>disease free survival after 2 and 4 years</measure>
    <time_frame>2 and 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to remission</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative organ damage</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side-effects</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANCA titres over time</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Wegener's Granulomatosis</condition>
  <condition>Vasculitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mycophenolate and steroids as remission induction, followed by azathioprine maintenance therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>2000 mg mycophenolate per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First or second relapse ANCA-associated vasculitis

          -  PR3- or MPO-ANCA antibodies present or histological proof of relapse

          -  Adult

        Exclusion Criteria:

          -  Severe alveolar bleeding or (imminent) respiratory failure

          -  Renal failure (serum creatinine &gt;500 umol/L or dialysis)

          -  Maintenance therapy before start of study consisting of: cyclophosphamide &gt; 100 mg/day
             or prednisolone &gt;25 mg/day

          -  Intolerance or allergy for cyclophosphamide, mycophenolate mofetil or azathioprine

          -  Gravidity or inadequate anticonception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Coen Stegeman, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia M. Stassen, M.D., Ph.D.</last_name>
    <phone>+31433876543</phone>
    <email>p.stassen@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Coen A. Stegeman, M.D., Ph.D.</last_name>
    <phone>+31503616161</phone>
    <email>c.a.stegeman@int.umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Stassen, M.D.</last_name>
      <phone>+31503611295</phone>
      <email>p.m.stassen@int.umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Coen Stegeman, M.D., Ph. D.</last_name>
      <phone>+31503616161</phone>
      <email>c.a.stegeman@int.umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Stassen, M.D. pH.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Stegeman CA; Cohen Tervaert JW. Mycophenolate mofetil for remission induction in patients with active Wegener's Granulomatosis (WG) intolerant for cyclophosphamide. J Am Soc Nephrol(11):98A, 2000</citation>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2005</study_first_submitted>
  <study_first_submitted_qc>February 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2005</study_first_posted>
  <last_update_submitted>February 12, 2009</last_update_submitted>
  <last_update_submitted_qc>February 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>University Medical Center Groningen</name_title>
    <organization>Dept of Nephrology</organization>
  </responsible_party>
  <keyword>Induction therapy</keyword>
  <keyword>ANCA-associated vasculitis</keyword>
  <keyword>Wegener's granulomatosis</keyword>
  <keyword>microscopic polyangiitis</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

